Home » Newsletters » BioWorld Science

BioWorld Science

July 15, 1998

View Archived Issues

Antipsychotic drug trifluoperazine inhibits growth of mycobacterial isolates

Potent, broad-spectrum cephalosporin antibiotics in the pipeline at Roche

Fast track designation granted for FGN-1 in APC

Abbott completes acquisition of Murex

FDA requests additional analysis of Exelon before U.S. approval

Mylan announces copromotion agreement

INVICORP approved for launch in Denmark

NeXstar initiates second part of MiKasome phase II trial and reports preliminary findings

Italian launch for Prograf announced

Cyclacel licenses novel drug delivery technology from CNRS

Lilly describes serotonergic agents for treating obesity, CNS disorders

Centrally acting muscarinic agents discovered at American Home Products

Neurocrine Biosciences takes over clinical development of benzodiazepine

World's first brain cell transplant performed in stroke patient

TSL-225, a dipeptide inhibitor of dipeptidyl peptidase IV

CR-2945, a promising new anxiolytic agent in preclinical testing

NIH finds new selective ligands for studying P2X1 purinoceptors

New semisynthetic macrolide antibiotics designed by Pliva

Mitsui Toatsu describes potent, long-acting and orally bioavailable antipsychotic agents

Indolocarbazoles for prostate disorders jointly developed by Cephalon and Kyowa Hakko

Preliminary evidence of antidepressant effect for igmesine, a sigma ligand

Company Profile: Amur

ID Biomedical and Mitsubishi Chemical sign distribution agreement

M-100907 improves positive and negative symptoms and is well tolerated in schizophrenics

Clinical evaluation of AlloMune transplantation system begins

Orally active gastric antisecretory agents synthesized and evaluated at Daiichi

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...